Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center

Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center

Abemaciclib significantly improves invasive disease-free survival when combined with endocrine therapy in clinical high-risk patients with HR+/Her2− early breast cancer (eBC). The objective of the following study was to model how many patients with eBC would be available for adjuvant treatment with...

Full description

Bibliographic Details
Main Authors: Dominik Dannehl, Lea L. Volmer, Martin Weiss, Sabine Matovina, Eva-Maria Grischke, Ernst Oberlechner, Anna Seller, Christina B. Walter, Markus Hahn, Tobias Engler, Sara Y. Brucker, Andreas D. Hartkopf
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Journal of Personalized Medicine
Subjects:
breast cancer
oncology
CDK 4/6
systemic therapy
monarchE
abemaciclib
Online Access:https://www.mdpi.com/2075-4426/12/3/382

Similar Items

Similar Items